Over the past 15 years genetic sequencing costs have fallen 100x faster than computing costs. Moore’s law does not keep up.

Today, clinical genetics labs generate terabytes of sequencing data that needs to be analysed and interpreted quickly to diagnose and treat patients efficiently.

Using software, machine learning and decades of experience, we are playing our part in overcoming this challenge.

Genomic regions analysed by users of Euformatics software globally


Clinical NGS industry expected to triple within the decade

The next-generation sequencing (NGS) market is projected to reach USD 24.4 billion by 2025 from USD 7.8 billion in 2019, at a CAGR of 20.9%. The growth of this market is largely driven by the advancements in and declining costs of NGS platforms and the improving regulatory and reimbursement scenario for NGS-based diagnostic tests.

Grand View Research logo

Grand View Research

Next Generation Sequencing Market Size, Share & Trends Analysis Report, February 2021

Clinical research is expected to be the fastest-growing end-use segment from 2021 to 2028.

Our global distribution partner network

Are you our next partner?

We are building a global partner network to help leverage the full benefits of NGS technologies in the clinical environment. If you understand the healthcare market locally and want to include state-of-the-art clinical interpretation and quality control software in your portfolio please reach out to us.

Here are a few examples of our channel partners:

BC PlatformsGlobal
Sintese BiotecnologiaBrazil
Al JeelSaudi Arabia

How we got here – key milestones:


Euformatics is founded

Euformatics is founded by four friends and colleagues, Christophe, Jukka, Jussi and Juha. Experts in software engineering, systems biology, and high-throughput measurements technologies in genomics, they see that the genomics landscape is changing, and that a software tool for helping interpret huge amounts of genomic data will soon be needed.

2011 – 2012

First product ideas born

What will later become omnomicsNGS is launched in its first iteration in close collaboration with a Finnish hospital.


Office upgrade

After a few years in a cold, wooden barracks in Otaniemi, the team move to Keilaniemi near to the Nokia headquarters.


Major new partnership

A milestone partnership with BC Platforms is signed. omnomicsNGS and quality control tool omnomicsQ are sold as BC|Predict and BC|Q on top of BC Platforms genomic data management solution. Customers ask if omnomicsQ could be used for validation; a new idea germinates.


We are profitable!

After 5 years with red numbers, the company reaches its first year of profitability, no longer reliant on external funding. We also make our first appearance at a conference, at ESHG in Glasgow. Our relationship with EMQN starts there and omnomicsV for NGS test validation is launched.


Recognition grows

A sign of the quality of the products (literally) – Euformatics partners with global external quality assessors EMQN and UKNEQAS to provide the backbone of the newly created NGS EQA, a relationship that continues to this day.


GEMMA project launches

Euformatics is selected as the analysis software provider for a multi-year international research project that aims to increase our understanding of autism spectrum disorders through studying the role of gut bacteria and the human genome. The project is a multidisciplinary effort that brings together leading pediatric medical research institutions in the US and Europe.


R&D and growth

We spend 60% of our revenue on R&D, and 85% of revenue comes from sales outside of Finland.



The pandemic temporarily brings the world to a standstill. Tommi starts as new CEO with an ambition to grow the company to the next level. The strategy is updated and everyone rallies behind it to deliver.


Back to growth

We worked hard to identify, negotiate and sign new channel partners and customers on all continents and helping the new recruits Tim, Miguel, Iina, Makenzi, Andrey, Benjamin and Rafael get up to speed fast. New offering for pathogen variant surveillance is delivered to the market with funding from Amazon and SYNLAB being the lead customer.


Deepening key partnerships

We focused on building strategic collaboration with selected industry and channel partners globally. We invested into ISO 13485 Quality Management System development and implementation of IVDR compliant NGS workflows together with our customers.


Investing in oncology

After winning two major contracts for solid tumor and liquid biopsy related bioinformatics development for separate groups of central European hospitals as buyers we had to deliver on our proposal. These contracts pushed the state-of-the-art in oncology testing and our tools got stronger in cancer diagnostics as a result. Third consecutive year of profitable growth for the company.

What does the future hold?


Common target

As Euformatics reaches the milestone of having more than a dozen customers on each major continent (excluding Antarctica), Tommi makes good on his promise to throw our ever-misbehaving printer out of the window. To be filmed and celebrated by everyone in the company 😊